| Literature DB >> 22848164 |
Samer Hasan1, Hussein Al Ali, Mothanna Al-Qubaisi, Mohd Zobir Hussein, Maznah Ismail, Zulkarnain Zainal, Muhammad Nazrul Hakim.
Abstract
A controlled-release formulation of an antihistamine,Entities:
Keywords: cetirizine hydrochloric acid; histamine release; nanocomposite; rat basophilic leukemia (RBL-2H3) cells; zinc-layered hydroxide
Mesh:
Substances:
Year: 2012 PMID: 22848164 PMCID: PMC3405893 DOI: 10.2147/IJN.S30809
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1Powder X-ray diffraction patterns of (A) zinc oxide, (B) CETN, and (C) cetirizine.
Abbreviation: CETN, cetirizine nanocomposite.
Figure 2Structure of cetirizine at different pH (A–C) and molecular structure model of cetirizine intercalated between the interlayer of ZLH (D).
Abbreviation: ZLH, zinc-layered hydroxide.
Figure 3Fourier transform infrared spectra of (A) cetirizine and (B) the cetirizine nanocomposite.
Fourier transform infrared assignment for cetirizine and CETN21,29
| Assignments | Cetirizine | CETN |
|---|---|---|
| ν (O–H) | 3432 for O–H in carboxylic group | 3424 in the layer; H2O |
| ν (CHar) | 3044–3023 | – |
| ν (CH2) | 2984–2949 | 2958–2817 |
| ν (OH) dimmer | 2628, 2505 and 2379 | – |
| ν (NH+) cyclic | 2217 | – |
| ν (COOH) | 1740 | – |
| ν (φ. parasubst) | 1601 | 1602 |
| ν (φ. monosubst) | 1496, 1077 and 758 | 1488 |
| ν (C–Cl) | 1457 | 1453 |
| ν (C–O) in carboxylic group | 1435, 1383, 1356 and 1319 | – |
| δ (O–H) | 1284, 1274, 1263 and 1242 | – |
| δ (CH2 CH2O CH2) | 1185 | 1130 |
| 2 adj φ | 846 and 809 | 853 and 804 |
| ν (CH monosubst) | 758 | 758 |
| Zn–O and Zn–OH | – | 503 |
| νas(COO−) | – | 1602 |
| νs(COO−) | – | 1408 |
Abbreviations: adj, adjacent; CETN, cetirizine nanocomposite; monosubst, monosubstitution; parasubst, parasubstitution.
Figure 4Thermogravimetric and differential thermogravimetric analyses of (A) cetirizine and (B) the cetirizine nanocomposite.
Physico-chemical properties of zinc oxide and the cetirizine nanocomposite (CETN)
| Sample | C (%) | H (%) | N (%) | Zn (% w/w) | Anion (% w/w) | BET surface area m2/g | BJH pore volume cm3/g | BJH average pore diameter Å |
|---|---|---|---|---|---|---|---|---|
| ZnO | – | – | – | (80.3) | – | 6 | 0.01 | 111 |
| CETN | 32.1 | 4.1 | 3.5 | 32.3 | 49.4 | 24 | 0.71 | 96 |
Notes: Value in the parentheses is a theoretical value.
Estimated from carbon, hydrogen, nitrogen and sulfur analysis data;
estimated from atomic absorption spectroscopy analysis;
estimated from UV.
Abbreviations: BET, Brunauer, Emmett, and Teller method; BJH, Barrett–Joyner–Halenda method; ZnO, zinc oxide; CETN, cetirizine nanocomposites.
Figure 5Adsorption-desorption isotherms for zinc oxide and CETN (A) and Barret–Joyner–Halenda method pore size distribution for zinc oxide and CETN (B).
Abbreviation: CETN, cetirizine nanocomposite.
Figure 6Field emission scanning electron microscope image of zinc oxide (A and B) and the cetirizine nanocomposite (C and D).
Figure 7(I) Release profiles of cetirizine from the cetirizine nanocomposite at pH 7.4 (A) and pH 4.8 (B) up to 5 hours; (II) release profiles of cetirizine up to 83 hours.
Note: Inset shows the release profiles of cetirizine from its physical mixture of cetirizine with zinc layered hydroxide at pH 7.4 (C) and pH 4.8 (D).
Figure 8Fitting of the data of cetirizine released from the cetirizine nanocomposite into various solutions to the first-, pseudo-second order kinetics and parabolic diffusion model for pH 7.4 (A–C) and pH 4.8 (D–F).
Correlation coefficient (R2), rate constant (k), and half time (t1/2) obtained by fitting the data of the release of cetirizine from the cetirizine nanocomposite (CETN) into phosphate buffer solution at pH 7.4 and pH 4.8
| Aqueous solution | Saturation release (%) | R2 | Pseudo-second order | |||
|---|---|---|---|---|---|---|
|
|
| |||||
| Pseudo-first order | Pseudo-second order | Parabolic diffusion | Rate constant, k (g/mg · h) | t1/2 (h) | ||
| pH 7.4 | 96 | 0.7867 | 0.9967 | 0.7555 | 0.003 | 3.80 |
| pH 4.8 | 97 | 0.8277 | 0.9994 | 0.5391 | 0.008 | 1.36 |
Figure 9Trypan Blue assays of normal Chang liver cells after 24 hours of treatment with zinc-layered hydroxide (ZLH) and cetirizine nanocomposite (CETN).
Viability of normal Chang liver cells after 24 hours’ treatment with zinc-layered hydroxide (ZLH) and cetirizine nanocomposite (CETN)
| Concentrations (μg/mL) | Viability (%) | |
|---|---|---|
|
| ||
| ZLH | CETN | |
| 0.00 | 100.0 | 100.0 |
| 7.81 | 102.9 | 99.4 |
| 15.62 | 99.4 | 98.9 |
| 31.25 | 97.7 | 95.9 |
| 62.5 | 91.8 | 91.8 |
| 125 | 87.1 | 81.9 |
| 250 | 69.0 | 64.3 |
| 500 | 63.7 | 58.5 |
| 1000 | 23.4 | 22.2 |
Figure 10A–CHistamine release response of rat basophilic leukemia cells treated at different concentrations of cetirizine, cetirizine nanocomposite, and zinc-layered hydroxide.
Figure 11Percentage inhibition of histamine release into rat basophilic leukemia cells at different concentrations of cetirizine (CET), cetirizine nanocomposite (CETN), and zinc-layered hydroxide (ZLH).
Inhibition percentage of histamine release in rat basophilic leukemia cells by free cetirizine, the cetirizine nanocomposite (CETN), zinc-layered hydroxide (ZLH), and cetirizine intercalated into CETN
| Concentration (ng/mL) | Inhibition (%) | |||
|---|---|---|---|---|
|
| ||||
| Cetirizine | ZLH | CETN | Cetirizine in CETN | |
| 1000 | 80.0 | 22.5 | 83.8 | – |
| 500 | 73.7 | 16.2 | 77.3 | 67.6 |
| 250 | 58.1 | 15.3 | 66.5 | 62.0 |
| 125 | 50.2 | 4.0 | 57.2 | 62.5 |
| 62.5 | 29.0 | 1.2 | 40.8 | 56.0 |
| 31.25 | 19.3 | 0.6 | 30.6 | 40.2 |
| 15.63 | 8.5 | −1.1 | 11.7 | 31.7 |
Note:
Inhibition (%) by intercalated cetirizine into CETN = (inhibition by CETN at 1000 ng/mL – inhibition by ZLH at 500 ng/mL), because the loading of cetirizine into CETN is 49.4%.